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BACKGROUND
Metagenomic next-generation sequencing (NGS) of cerebrospinal fluid (CSF) has 
the potential to identify a broad range of pathogens in a single test.
METHODS
In a 1-year, multicenter, prospective study, we investigated the usefulness of 
metagenomic NGS of CSF for the diagnosis of infectious meningitis and encepha-
litis in hospitalized patients. All positive tests for pathogens on metagenomic NGS 
were confirmed by orthogonal laboratory testing. Physician feedback was elicited 
by teleconferences with a clinical microbial sequencing board and by surveys. 
Clinical effect was evaluated by retrospective chart review.
RESULTS
We enrolled 204 pediatric and adult patients at eight hospitals. Patients were se-
verely ill: 48.5% had been admitted to the intensive care unit, and the 30-day 
mortality among all study patients was 11.3%. A total of 58 infections of the 
nervous system were diagnosed in 57 patients (27.9%). Among these 58 infections, 
metagenomic NGS identified 13 (22%) that were not identified by clinical testing 
at the source hospital. Among the remaining 45 infections (78%), metagenomic 
NGS made concurrent diagnoses in 19. Of the 26 infections not identified by 
metagenomic NGS, 11 were diagnosed by serologic testing only, 7 were diagnosed 
from tissue samples other than CSF, and 8 were negative on metagenomic NGS 
owing to low titers of pathogens in CSF. A total of 8 of 13 diagnoses made solely 
by metagenomic NGS had a likely clinical effect, with 7 of 13 guiding treatment.
CONCLUSIONS
Routine microbiologic testing is often insufficient to detect all neuroinvasive 
pathogens. In this study, metagenomic NGS of CSF obtained from patients with 
meningitis or encephalitis improved diagnosis of neurologic infections and pro-
vided actionable information in some cases. (Funded by the National Institutes of 
Health and others; PDAID ClinicalTrials.gov number, NCT02910037.)
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The existing paradigm for diagnos-ing infections relies on the physician for-mulating a differential diagnosis on the 
basis of a patient’s history, clinical presentation, 
and imaging findings, followed by serial labora-
tory testing. This traditional approach is partic-
ularly challenging for neuroinflammatory dis-
eases given overlapping clinical manifestations 
of infectious and noninfectious causes, a lack of 
diagnostic tests for rare pathogens, and the lim-
ited availability and volume of central nervous 
system (CNS) samples owing to the requirement 
for invasive procedures, such as lumbar puncture 
or brain biopsy. Thus, a cause for acute meningo-
encephalitis cases is not identified in approxi-
mately 50% of patients.1-3 Failure to obtain a 
timely diagnosis in patients with CNS disease 
contributes to poor patient outcomes, increased 
patient and family anxiety, and a high cost bur-
den to the health care system.4
Metagenomic next-generation sequencing (NGS) 
is a promising approach for the diagnosis of 
infectious disease because a comprehensive 
spectrum of potential causes — viral, bacterial, 
fungal, and parasitic — can be identified by a 
single assay.5,6 However, published reports de-
scribing the usefulness of metagenomic NGS in 
patients with meningitis or encephalitis are 
limited to individual patients or small, retrospec-
tive case series.7 The question remains whether 
the diagnostic performance and yield of clinical 
metagenomic NGS testing for neurologic infec-
tions justifies its wider adoption by the medical 
community.
We performed a 1-year, prospective, multi-
center study involving hospitalized patients pre-
senting with idiopathic meningitis, encephalitis, 
or myelitis (the Precision Diagnosis of Acute 
Infectious Diseases [PDAID] study). We recently 
described the analytic sensitivity and specificity 
of the metagenomic NGS assay of CSF for iden-
tification of pathogens in patients with neuro-
logic infection confirmed by routine diagnostic 
testing, including culture and polymerase-chain-
reaction (PCR) assay.8,9 This study was designed 
to evaluate the real-life clinical performance and 
effect of the metagenomic NGS assay in com-
parison with conventional microbiologic testing 
in patient-care scenarios in which the test is 
likely to be used. As such, results of metage-
nomic NGS were reported in the electronic medi-
cal record (EMR) and used for contemporaneous 
patient-care decisions by treating physicians.
Me thods
Study Design
This study was a 1-year, multicenter, prospective 
case series in which patients were enrolled on 
the basis of a particular exposure (i.e., idio-
pathic meningitis with or without encephalitis, 
myelitis, or both) and then followed over time to 
assess for the occurrence of the outcome (i.e., 
results of metagenomic NGS of CSF). Prospec-
tive enrollees were identified by means of physi-
cian referral, computerized provider-order entry, 
patient chart review, or screening of daily EMR 
reports (see the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org). 
Given the constraints on funding and clinical-
testing capacity, sample-size estimates (300 pa-
tients) were based on convenience without formal 
statistical considerations. The target condition 
was idiopathic meningitis, encephalitis, or myeli-
tis in patients who had not received a diagnosis 
at the time of enrollment (Table S1 in the Supple-
mentary Appendix). The index test was a metage-
nomic NGS assay of CSF, and the reference 
standard was a composite of conventional test-
ing and orthogonal confirmatory testing of 
positive tests for pathogens on metagenomic 
NGS only.
Because standard reference results for diag-
nosis of meningitis and encephalitis were not 
available (owing to the varying extent of diag-
nostic testing done at each hospital, a lack of 
detailed performance characteristics for each 
test performed locally, and a lack of comprehen-
sive reference testing for meningitis and encepha-
litis), obtaining unbiased estimates of sensitivity 
and specificity was not possible. Thus, the com-
parative performance measures of metagenomic 
NGS relative to conventional testing are reported 
as positive percent agreement and negative per-
cent agreement with the composite reference 
standard (see the Supplementary Appendix, includ-
ing Fig. S1), in accordance with statistical guid-
ance from the Food and Drug Administration.10
Metagenomic NGS of CSF
CSF samples were batched for weekly processing 
in the Clinical Laboratory Improvement Amend-
ments–certified clinical microbiology laboratory 
at the University of California, San Francisco 
(UCSF), with the use of a protocol for the vali-
dated metagenomic NGS assay, as described 
previously.8,9 RNA and DNA libraries that were 
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generated from CSF samples obtained from pa-
tients were each sequenced to a depth of 5 mil-
lion to 10 million single-end, 140-base-pair 
reads on an Illumina HiSeq instrument in rapid-
run mode. Automated computational analysis 
of metagenomic NGS data was performed with 
the use of a modified clinical version of the 
Sequence-based Ultra-Rapid Pathogen Identifi-
cation (SURPI) pipeline11; the modified SURPI+ 
pipeline incorporated taxonomic classification 
for species-specific identification and a graphical 
user interface (see the Supplementary Appendix). 
Detection of pathogens according to type was 
reported on the basis of preestablished thresh-
old criteria.8,9
After review by the laboratory director, results 
were immediately reported in the patient EMR, 
with follow-up by discussion with the treating 
physicians through real-time teleconferencing at 
a meeting of the clinical microbial sequencing 
board (see the Supplementary Appendix). Physi-
cian feedback was elicited during these meetings 
regarding the effect of metagenomic NGS results 
on clinical reasoning, management of patient 
care, or both. Standardized physician surveys 
that were conducted before and after reporting 
of metagenomic NGS results were also used to 
elicit feedback (see the study protocol, available 
at NEJM.org).
Chart Review
The study enrollment target was 300 patients 
over the 1-year study period. All patients who 
were enrolled in the study provided written in-
formed consent. Final clinical diagnoses for the 
patients who completed the study were adjudi-
cated by retrospective, in-depth chart review in-
dependently performed by a board-certified neu-
rologist (the first author) and infectious-diseases 
physician and microbiologist (the last author).
Orthogonal confirmation of discrepant re-
sults was performed with the use of a validated 
clinical assay (preferred) or PCR testing in a re-
search laboratory. The result of the orthogonal 
confirmatory test was considered to be accurate 
and used to resolve the discrepancy. Confirma-
tion was done to minimize incorporation bias by 
the inclusion of unverified results of the index 
text (i.e., metagenomic NGS) into the definition 
of an infectious diagnosis.12 Incidental findings 
and laboratory-reported contaminants were also 
recorded. Any discrepancies in assignment of 
diagnoses were resolved by direct communica-
tion with treating physicians or by mutual con-
sensus.
R esult s
Patient Characteristics
Between June 1, 2016, and July 1, 2017, a total of 
482 patients were screened and referred across 
eight participating sites for review and prospec-
tive enrollment in this study (Fig. 1A). A total of 
285 patients met the enrollment criteria (Table 
S1 in the Supplementary Appendix), 214 were 
enrolled, and 204 completed the study. The aver-
age age of the 204 patients (55.9% were male) 
was 39.6 years; 46 patients (22.5%) were 18 years 
of age or younger (Table 1). The cohort primar-
ily included patients with isolated meningitis (70 
patients [34.3%]) or encephalitis (130 patients 
[63.7%]), with only 2.0% presenting with myeli-
tis (4 patients). A total of 86.3% of the patients 
(176 patients) presented with an acute condition, 
whereas the remaining 13.7% (28 patients) pre-
sented with an acute exacerbation of a chronic 
condition. Most of the patients (193 patients 
[94.6%]) were enrolled from California hospitals 
(Fig. 1B), and 40.7% (83 patients) were immuno-
compromised (Table 1). Study patients had a 
mean length of stay of 27.9 days (median, 17; 
range, 1 to 246) and were severely ill: 48.5% (99 
patients) were admitted to the intensive care unit 
(ICU). Critically ill patients who were enrolled at 
the University of California, Los Angeles, and 
UCSF (69 of the 146 patients [47.3%] who were 
enrolled at these two sites) spent an average of 
17.8 days in the ICU. The overall 30-day mortal-
ity (both in the hospital and out of the hospital) 
was 11.3% (23 patients).
CSF Analysis by Metagenomic NGS Testing
CSF samples from all 204 patients were analyzed 
by means of metagenomic NGS and the auto-
mated SURPI+ computational pipeline, as de-
scribed previously (Fig. 1C).11 The mean labora-
tory turnaround time from initiation of CSF 
sample processing by nucleic acid extraction to 
completion of SURPI+ analysis was 90 hours.
Performance of Metagenomic NGS Relative  
to Conventional Testing
An etiologic diagnosis was identified in 50.5% 
of the study patients (Fig. 2A), with infectious 
(27.9%) and autoimmune (8.3%) as the most com-
mon diagnostic categories. A composite reference 
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standard that combined results from orthogo-
nally confirmed metagenomic NGS with conven-
tional testing was used to evaluate the compara-
tive performance of metagenomic NGS (see the 
Supplementary Appendix). Of 58 infections in 57 
patients, 19 (33%) were diagnosed by both con-
ventional testing and metagenomic NGS, 26 
(45%) by conventional testing only, and 13 (22%) 
by metagenomic NGS only (Table 2; also see the 
Case Vignettes in the Supplementary Appendix).
Figure 1. Overview of the Study.
Panel A shows the flow of patients through the study. Panel B shows 8 participating sites. The size of the circle is proportional to the 
number of patients enrolled at a given site. Panel C shows the protocol for the metagenomic next-generation sequencing (NGS) assay. 
After samples of cerebrospinal fluid (CSF) are received in the clinical laboratory, nucleic acid (DNA and RNA) is isolated, followed by 
construction of a metagenomic NGS library and sequencing. The metagenomic NGS data are analyzed with the use of an automated 
computational pipeline (Sequence-based Ultra-Rapid Pathogen Identification [SURPI+]), with results reported in the electronic medical 
record (EMR) after review by the laboratory director. CHCO denotes Children’s Hospital Colorado; CHLA Children’s Hospital Los Angeles; 
CNMC Children’s National Medical Center; SJCRH St. Jude Children’s Research Hospital; UCD University of California, Davis; UCLA Uni-
versity of California, Los Angeles; UCSF University of California, San Francisco; and ZSFGH Zuckerberg San Francisco General Hospital.
A Screening, Enrollment, and Follow-up
C Protocol for Metagenomic NGS Assay
B Study Sites
285 Met criteria for enrollment
482 Patients were assessed
for eligibility
213 Were identified by chart review
165 Were identified by physician
referral
58 Were identified by automated
EMR report
46 Were identified by provider-
order entry
197 Did not meet criteria
for enrollment
214 Were enrolled in study
71 Were not enrolled in study
34 Had inadequate CSF
volume (<0.5 ml)
19 Declined to participate
18 Were discharged from
hospital or could not
be contacted
204 Completed the study
10 Withdrew or were withdrawn
6 Did not provide written consent 
or could not be contacted
3 Were withdrawn by surrogate
1 Withdrew 
ZSFGH
(N=8)
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(N=110)
UCD
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In total, metagenomic NGS identified 32 in-
fections, as compared with 27 infections with 
conventional direct-detection testing alone (de-
fined as culture, PCR, or antigen testing of CSF 
without including serologic testing or testing of 
samples other than CSF) (Fig. S1 in the Supple-
mentary Appendix). High host DNA background, 
which can decrease the sensitivity of metage-
nomic NGS testing, was typically seen at CSF 
cell counts of more than 200 cells per cubic 
milliliter (Fig. 2B).
Infections that were diagnosed solely by 
metagenomic NGS included St. Louis encephali-
tis virus (SLEV),15 hepatitis E virus,16,17 and Strep-
tococcus agalactiae; these pathogens had not been 
considered by the treating clinicians for the pa-
tients. Metagenomic NGS also identified patho-
gens for which there was some degree of clinical 
suspicion, although conventional testing had 
returned negative (neisseria, Nocardia farcinica, 
Candida tropicalis, Enterobacter aerogenes [now re-
named Klebsiella aerogenes], S. mitis, and Enterococ-
cus faecalis). Other orthogonally confirmed 
metagenomic NGS findings included microbes 
that were of unclear significance (longitudinal 
detection of MW polyomavirus in an immuno-
compromised child18), were directly related to 
noninfectious clinical syndromes (Epstein–Barr 
virus [EBV] detection in a patient with EBV-
positive primary hepatic lymphoma and associ-
ated encephalitis), or were not specifically tested 
for but would probably have been positive by 
conventional testing (two cases of enteroviral 
meningitis).
In 26 patients, metagenomic NGS testing of 
CSF was negative even though conventional mi-
crobiologic testing across all tissue types re-
vealed an infectious cause (Table S2 in the Sup-
plementary Appendix). These clinical false 
negative cases by metagenomic NGS fell into 
three categories: cases diagnosed by serologic 
testing alone (11 infections), for which conven-
tional direct-detection tests from CSF (e.g., cul-
ture, PCR, and antigen-based testing) were also 
negative; cases diagnosed from samples other 
than CSF (7 infections), such as brain biopsy; 
and cases negative by metagenomic NGS owing 
to low titers of pathogens in CSF (8 infections), 
as evidenced by conventional microbiologic tests 
that were borderline positive or had discordant 
results. The last category included infections 
from Mycobacterium bovis, M. tuberculosis, Cryptococ-
cus neoformans, Propionibacterium acnes, fusobacte-
rium, Staphylococcus aureus, cytomegalovirus, and 
herpes simplex virus type 2.
It is notable that reads mapping to all 6 
missed bacterial and fungal pathogens were 
detected, but their abundance did not meet pre-
established reporting thresholds (see the Supple-
mentary Appendix).9 Metagenomic NGS also 
detected 19 viral infections adjudicated as inci-
dental to the neurologic illness after chart re-
view (Table S3 in the Supplementary Appendix). 
In 3 cases, results of metagenomic NGS were 
found to be false positives after discrepancy test-
ing (pantoea, S. aureus, and S. agalactiae) and were 
attributed to sample contamination from the 
environment or normal human flora.
Clinical Microbial Sequencing Board
A clinical microbial sequencing board was es-
tablished to hold weekly teleconferences for re-
view of metagenomic NGS in clinical context 
and to communicate results of supplementary 
metagenomic NGS analyses, including species 
and strain typing, reporting of potential patho-
gens detected below preestablished thresholds, 
analysis of longitudinally collected samples in 
clinical context, and characterization of drug 
resistance (Figs. 2C and 3). During discussions 
of the clinical microbial sequencing board, clini-
cians expressed that the results of metagenomic 
NGS were useful for providing reassurance to 
the patient, surrogate, or both (e.g., SLEV); sup-
porting the clinical decision to stop unnecessary 
empirical treatments (e.g., acyclovir for empiri-
cal coverage of herpesvirus infections); helping 
to rule out coinfections (e.g., detection of EBV 
alone in cases of post-transplantation lymphopro-
liferative disease or lymphoma with encephali-
tis); diagnosing infectious syndromes (e.g., CNS 
escape in human immunodeficiency virus type 1 
infection23); and expediting appropriate treat-
ment (e.g., chemotherapy for lymphoma or im-
munosuppressive agents, including glucocorti-
coids, for acute demyelinating encephalomyelitis) 
in suspected noninfectious cases, as well as for 
epidemiologic purposes, such as virus genotyp-
ing (e.g., positive enterovirus cases).
Some clinicians expressed a wish that the 
turnaround time for metagenomic NGS testing 
could be shortened to increase the likelihood 
that the results would be clinically actionable. 
For the case of MW polyomavirus identified by 
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Characteristic Value
Age
Mean — yr 39.6
Distribution — no. (%)
0–2 yr 5 (2.5)
3–12 yr 25 (12.3)
13–18 yr 16 (7.8)
19–25 yr 17 (8.3)
26–40 yr 40 (19.6)
41–60 yr 53 (26.0)
>60 yr 48 (23.5)
Male sex — no. (%) 114 (55.9)
Syndrome — no. (%)
Meningitis alone 70 (34.3)
Encephalitis with or without meningitis 130 (63.7)
Myelitis with or without meningitis 4 (2.0)
Exacerbation of chronic condition — no. (%)† 28 (13.7)
Institution — no. (%)
University of California, San Francisco 110 (53.9)
University of California, Los Angeles 36 (17.6)
University of California, Davis 31 (15.2)
Children’s Hospital Los Angeles 8 (3.9)
Zuckerberg San Francisco General Hospital 8 (3.9)
Children’s Hospital Colorado 6 (2.9)
St. Jude Children’s Research Hospital 3 (1.5)
Children’s National Medical Center 2 (1.0)
Immunocompromised — no. (%) 83 (40.7)
HIV-1 21 (10.3)
Solid-organ transplant 14 (6.9)
Bone marrow transplant 13 (6.4)
Chemotherapy 14 (6.9)
Immunosuppression for non-neoplastic condition 14 (6.9)
Congenital condition 3 (1.5)
Other 4 (2.0)
Existing CNS hardware — no. (%)‡ 27 (13.2)
ICU admission — no. (%) 99 (48.5)
Death within 30 days — no. (%) 23 (11.3)
Mean Karnofsky performance-status score at time of discharge§ 64.6
Mean length of stay (range) — days
In hospital 27.9 (1–246)
In ICU¶ 17.8 (1–71)
Percentage of hospitalization time spent in ICU¶ 32.2
Median no. of days after hospital admission that CSF was collected for 
metagenomic NGS (range) — days‖
3.0 (0–219)
Table 1. Demographic and Clinical Characteristics of the 204 Patients.*
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metagenomic NGS testing in an immunocom-
promised child, one of the clinicians expressed 
that this result complicated clinical manage-
ment, because it remained unknown whether 
the detected virus played a pathogenic role in the 
child’s acute neurologic illness. Among the 13 
cases diagnosed solely by metagenomic NGS, 
treating physicians stated that the results of 
metagenomic NGS favorably affected their clin-
ical reasoning in 8 cases (62%) (Fig. 2D) (also 
see the Supplementary Appendix). In 7 of these 
8 cases, the results of metagenomic NGS guided 
therapy (Fig. 2E) (also see the Supplementary 
Appendix).
Discussion
We evaluated the clinical usefulness of metage-
nomic NGS for diagnosing neurologic infections 
in a series of patients with idiopathic acute men-
ingitis, encephalitis, or myelitis at the time of 
enrollment, in parallel with conventional micro-
biologic testing. Thus, we sought to define the 
real-life performance of metagenomic NGS test-
ing in a difficult-to-diagnose patient population 
for whom the assay is most likely to be per-
formed, given current issues of cost, accessibil-
ity, and turnaround time. The highest diagnostic 
yield resulted from a combination of metage-
nomic NGS of CSF and conventional testing, 
including serologic testing and testing of sample 
types other than CSF. In this selected popula-
tion, the metagenomic NGS assay identified 
more potential pathogens than conventional 
direct-detection testing of CSF (32 vs. 27). A total 
of 13 infections were diagnosed solely by meta-
genomic NGS. It is notable that 8 of these 13 
diagnoses had a clinical effect, with physicians 
adjusting treatment in 7 cases. These findings 
show that neurologic infections remain undiag-
nosed in a proportion of patients despite con-
ventional testing and demonstrate the potential 
usefulness of clinical metagenomic NGS testing 
in these patients.
The overall percentage of study patients with 
an infectious diagnosis (27.9% [57 patients]) is 
lower than the percentages reported in the litera-
ture of 29 to 60%.1-3 CSF samples for metage-
nomic NGS testing were obtained a median of 
3 days after initial presentation to the hospital. 
However, in 35.3% of the patients (72 patients), 
the only available CSF sample was obtained from 
a second or later lumbar puncture at a median 
of 8 days after presentation (e.g., CSF from an 
initial lumbar puncture that was performed at 
an outside, non–study-site hospital was not always 
available). As a result, CSF samples for metage-
nomic NGS testing on these 72 patients were 
obtained later in the clinical course, often after 
patients were exposed to empirical antibiotics 
or after CSF samples had undergone multiple 
freeze–thaw cycles, thus potentially decreasing 
diagnostic yield. In addition, 42.6% of the pa-
tients who were enrolled in the study (87 of 204) 
were identified by physician referral, which 
probably biased enrollment toward patients with 
Characteristic Value
Mean total cost (range) — U.S. $**
All cases 211,706 (73,819–158,795)
Infectious cases†† 234,318 (42,368–110,840)
*  CNS denotes central nervous system, CSF cerebrospinal fluid, HIV-1 human immunodeficiency virus 1, ICU intensive 
care unit, IQR interquartile range, and NGS next-generation sequencing. Percentages may not total 100 because of 
rounding.
†  Symptoms had been present for more than 4 weeks.
‡  Included are patients with a shunt, pain pump, lumbar drain, or other neurosurgical hardware.
§  Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability. A score of 
60 to 70 indicates that the patient requires occasional assistance but is able to care for most needs. Data were avail-
able for 191 patients.
¶  Data are for patients enrolled at the University of California, San Francisco (UCSF), and University of California, Los 
Angeles (UCLA) who were admitted to the ICU (69 patients).
‖  Data do not include patients for whom an earlier CSF sample obtained at an outside hospital was used (13 patients 
from whom CSF was obtained a median of 3 days before transfer to a study site).
**  Data are for total (hospital and professional billing) costs paid for UCSF patients only (110 patients).
††  Data are for UCSF patients with an infectious diagnosis only (30 patients).
Table 1. (Continued.)
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cases that were particularly challenging to di-
agnose.
In 8 of 13 samples that yielded a diagnosis by 
metagenomic NGS only, the causative pathogen 
was either not considered by treating clinicians 
or had tested negative by conventional testing 
and was therefore considered an unlikely cause. 
These findings highlight a key advantage of 
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CSF Cell Count (cells/mm3)
C Supplementary Metagenomic NGS Analyses (15 cases discussed
during CMSB meetings) 
E Clinical Effect (13 cases diagnosed by metagenomic NGS only)
D Clinician Feedback (13 cases diagnosed by metagenomic NGS only)
A Established Diagnoses in the Study Patients B High DNA or RNA Background and CSF Cell Count
5, Viral genotyping (SLEV, HEV, enteroviruses [3 cases])
2, Accurate species identification (Nocardia farcinica, Streptococcus mitis)
2, Detection of pathogen reads below reporting threshold (Mycobacter-
ium tuberculosis complex, astrovirus MLB1)
3, Detection and tracking of new or rare infectious agents (MW polyoma-
virus, Angiostrongylus cantonensis [2 cases])
2, Prediction of resistance to antiviral drugs (HIV-1)
1, Analysis of antibiotic-resistance genes (Enterobacter aerogenes)
RNA backgroundDNA background
7 (54%) Will affect management and treatment
1 (8%) Provided reassurance to patient or surrogate (SLEV)
1 (8%) Increased confidence in clinical decisions (neisseria) 
1 (8%) Provided reassurance that coinfection is not present 
(EBV-associated lymphoma)
1 (8%) Unclear clinical significance (MW polyomavirus)
2 (15%) Viral genotyping useful for epidemiologic purposes
(enterovirus)
N=204
57 (27.9%) Infectious
17 (8.3%) Autoimmune
3 (1.5%) Postinfectious
7 (3.4%) Neoplastic
1 (0.5%) Vascular
3 (1.5%) Toxic metabolic
15 (7.4%) Other
101 (49.5%) Unknown
Metagenomic
NGS only (N=13)
Conventional
testing (N=26) 
Both (N=19)
7 (54%) Enabled appropriate and targeted treatment
1 (8%) Provided reassurance to patient or surrogate (SLEV)
 
1 (8%) Had no effect, because clinical significance unclear (MW polyomavirus)
2 (15%) Had no effect, because patient already discharged from
hospital (enterovirus)
1 (8%) Helped to rule out coinfections; enabled patient to proceed with 
chemotherapy (EBV-associated lymphoma)
1 (8%) Supported clinical decisions to narrow coverage (neisseria)
 
S. agalactiae — treatment with an additional 4 wk of therapy with IV
 ceftriaxone and vancomycin 
S. mitis — narrowing of antibiotic therapy to IV cefepime; continuation
of antibiotics for 4 wk to treat CNS infection 
Enterococcus faecalis — narrowing of antibiotic therapy to IV vancomycin; 
discontinuation of meropenem
E. aerogenes — narrowing of antibiotic therapy to IV cefepime
and oral trimethoprim–sulfamethoxazole 
HEV — successful treatment with IV ribavirin after patient was 
readmitted with liver failure and consideration of liver transplantation 
Candida tropicalis — treatment with high-dose fluconazole and liposomal
amphotericin B (started empirically for elevated 1,3-β-D-glucan level) 
N. farcinica — long-term treatment with oral moxifloxacin and
minocycline
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metagenomic NGS — that it does not rely on a 
priori selection of targeted pathogens but rather 
is able to detect many potential infectious agents 
in a single assay.5,6,24 Thus, the unbiased ap-
proach of metagenomic NGS may be useful for 
diagnostic testing of CSF samples, because 
sample volume and availability are often limited. 
The results of metagenomic NGS can also be 
valuable even when concordant with results of 
conventional testing (19 of 32 infections detect-
ed by metagenomic NGS), not only providing re-
assurance that the conventionally obtained diag-
nosis is correct but also potentially detecting or 
ruling out coinfections, especially in immuno-
compromised patients.
Of the 26 infections missed by metagenomic 
NGS, 18 were diagnosed by serologic testing 
alone or from sample types other than CSF. Like 
culture, PCR, and antigen-based testing, metage-
nomic NGS is fundamentally a direct-detection 
method and relies on the presence of nucleic 
acid from the causative pathogen in the CSF 
sample. Thus, the serologic diagnoses of West 
Nile virus (4 infections), varicella–zoster virus 
(3), and neurosyphilis (2) (Table S2 in the Sup-
plementary Appendix) are not unexpected given 
the poor performance of corresponding patho-
gen-specific PCR assays for these organisms.25,26 
Indeed, among 8 of these 9 cases with remain-
ing CSF available, all 8 samples tested negative 
by pathogen-specific PCR. It is also not surpris-
ing that analysis of samples other than CSF, 
such as biopsy tissue or abscess f luid, estab-
lished the diagnosis for some cases in the study, 
given direct sampling of the local infection site.
Modeled after the “tumor board” concept in 
oncology, the clinical microbial sequencing 
board afforded an opportunity to discuss re-
ported results of metagenomic NGS in a clinical 
context, as well as to communicate additional 
information from supplementary metagenomic 
NGS analyses. Although the clinical usefulness 
of these analyses remains to be established, the 
generation and reporting of supplementary 
metagenomic NGS results are conceptually sim-
ilar to pathologist-interpreted genomic analyses 
of variants of unknown significance in onco-
logic testing,27 which provide useful information 
to guide physicians beyond straightforward re-
porting of a binary test result (i.e., variant “de-
tected” or “not detected”). However, clinical in-
terpretation of supplementary metagenomic NGS 
results may be challenging given the lack of a 
reference standard in many instances.
Preestablished clinical thresholds for report-
ing a positive test for pathogens on metagenomic 
NGS were intentionally conservative in order to 
minimize false positive detections.8,9 In six of 
eight cases missed by metagenomic NGS owing 
to low pathogen titers, species-specific reads 
from the causative pathogen could still be iden-
tified. This raises the question of whether it 
would be appropriate to establish more liberal 
reporting thresholds for high-priority pathogens 
than for organisms such as environmental bac-
teria that are of unclear clinical significance. 
Alternatively, low-abundance metagenomic NGS 
detection of high-priority pathogens, such as 
M. tuberculosis or astrovirus MLB2 (see the Sup-
plementary Appendix), could be discussed in set-
tings such as the clinical microbial sequencing 
board, thereby prompting additional diagnostic 
testing that targets the specific pathogen.
Although metagenomic NGS testing was still 
useful in identifying a potential causative organ-
Figure 2 (facing page). Results of Metagenomic NGS 
Testing and Clinical Effect.
Panel A shows the proportion and categories of estab-
lished diagnoses in the study patients. A diagnosis was 
made in 103 of 204 patients (50.5%) after routine clinical 
workup and metagenomic NGS testing of CSF. A total 
of 58 infections (pink circles) were identified in 57 pa-
tients (27.9%). Conventional testing included culture, 
polymerase-chain-reaction (PCR), serologic (antibody), 
and antigen testing of CSF and other body fluids or tis-
sues. Diagnoses in the “Other” category included re-
solving treated infection, idiopathic intracranial hyper-
tension, posterior reverse encephalopathy syndrome, 
postneurosurgical (chemical) meningitis, and hemo-
phagocytic lymphohistiocytosis. In Panel B, a plot shows 
the number and percentage of patients with high DNA 
or RNA background at designated intervals of CSF cell 
counts. The proportion of samples with high back-
ground (defined as samples in which the normalized 
read counts corresponding to the internal spiked DNA 
or RNA control did not meet preestablished thresholds) 
increases with increasing cell count. Panel C shows 
supplementary metagenomic NGS analyses discussed 
during meetings of the clinical microbial sequencing 
board (CMSB). Panel D shows clinician feedback for 
cases diagnosed solely by metagenomic NGS. Panel E 
shows the clinical effect of cases diagnosed solely by 
metagenomic NGS. The specific effect of metagenom-
ic NGS results on the initiation, discontinuation, or 
length of antibiotic or antiviral treatment is described. 
EBV denotes Epstein–Barr virus, HEV hepatitis E virus, 
HIV-1 human immunodeficiency virus type 1, IV intra-
venous, and SLEV St. Louis encephalitis virus.
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Microorganism
High Host 
Background Relevant Clinical Microbiologic Testing Orthogonal Confirmatory Testing
Concurrent diagnosis by metagenomic 
NGS and conventional microbio-
logic testing (19 infections)
Angiostrongylus cantonensis No CSF PCR assay for A. cantonensis (+) (CDC)
A. cantonensis No CSF PCR assay for A. cantonensis (+) (CDC)
Coxsackievirus B5† No CSF RT-PCR assay for EV (+), 800 copies/ml
Cryptococcus neoformans Yes CSF culture for C. neoformans (+); CSF 
cryptococcal antigen assay (+), 1:640
C. neoformans No CSF culture for C. neoformans (+); 
FilmArray Meningitis/Encephalitis  
panel, C. neoformans (+)
C. neoformans No CSF culture for C. neoformans (+)
EBV (encephalitis)‡ No CSF PCR assay for EBV (+),  
2000 copies/ml
EBV (PTLD-associated) No CSF qPCR assay for EBV (+), <50 IU/ml 
(Viracor)
Echovirus 11† No FilmArray Meningitis/Encephalitis panel, 
EV (+) (BioFire)
HHV-6§ No FilmArray Meningitis/Encephalitis panel, 
HHV-6 (+) (BioFire)
HHV-6§ No CSF PCR assay for HHV-6 (+),  
536,000 copies/ml (Viracor)
HIV-1 (encephalopathy) No CSF PCR assay for HIV-1 (+),  
6900 copies/ml (ARUP Laboratories)
HIV-1 (HIV escape) No CSF PCR assay for HIV-1 (+), 36,000  
copies/ml (ARUP Laboratories)
HSV-1 No CSF PCR assay for HSV-1 (+) by Simplexa 
(UCSF)
HSV-2 No CSF PCR assay for HSV-2 (+), 166,000  
copies/ml (Viracor)
JC polyomavirus No CSF PCR assay for JC polyomavirus (+), 
162,000 copies/ml (Viracor)
VZV No FilmArray Meningitis/Encephalitis panel, 
VZV (+) (BioFire)
VZV No FilmArray Meningitis/Encephalitis panel, 
VZV (+) (BioFire)
VZV Yes CSF PCR assay for VZV (+), 371,000  
copies/ml (Viracor)
Diagnosis by metagenomic NGS 
only (13 infections)
Candida tropicalis¶ No Serum and CSF 1,3-β-D-glucan (+);  
CSF culture (−)
CSF fungal 28S rRNA and ITS PCR  
assay, C. tropicalis (+) (UW)
EBV (lymphoma-associated)‖ No — CSF qPCR assay for EBV (+), 700 IU/ml 
(Viracor)
Echovirus 6† No — CSF RT-PCR assay for EV (+), con-
firmed by Sanger sequencing 
(UCSF)
Echovirus 30† No — CSF RT-PCR assay for EV (+), con-
firmed by Sanger sequencing 
(UCSF)
Table 2. Infections Diagnosed by Means of Metagenomic NGS.*
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Microorganism
High Host 
Background Relevant Clinical Microbiologic Testing Orthogonal Confirmatory Testing
Enterobacter aerogenes** Yes CSF bacterial culture (−); CSF bacterial  
16S rRNA PCR assay (−) (UW)
CSF PCR assay for E. aerogenes (renamed 
Klebsiella aerogenes) (+), confirmed 
by Sanger sequencing (UCSF)
Enterococcus faecalis†† No CSF bacterial culture (−); FilmArray 
Meningitis/Encephalitis panel (−)
CSF bacterial 16S rRNA PCR assay (−) 
(UW); brain biopsy, E. faecalis by 
culture (+) (SJCRH)
HEV No — CSF IgM assay for HEV (+); CSF IgG 
assay for HEV (−); CSF RT-PCR  
assay for HEV (+), 5.96 million  
copies/ml (ARUP Laboratories)
MW polyomavirus No — CSF PCR assay for MW polyomavirus 
(+), confirmed by Sanger sequenc-
ing (UCSF)
Neisseria meningitidis‡‡ Yes CSF Gram’s stain, gram-negative diplococ-
ci (+); CSF bacterial culture (−); CSF  
N. meningitidis antigen assay (−); 
FilmArray Meningitis/Encephalitis  
panel (−) (UCLA)
Neisseria, probably not N. meningitidis, 
by CSF metagenomic NGS and 
phylogenetic analysis
Nocardia farcinica§§ Yes CSF bacterial culture (−); CSF bacterial  
16S rRNA PCR assay (−) (UW)
CSF PCR assay for N. farcinica (+), con-
firmed by Sanger sequencing (UCSF)
SLEV No — CSF RT-PCR assay for SLEV (+) (CDC)
Streptococcus agalactiae¶¶ Yes CSF bacterial culture (−) FilmArray Meningitis/Encephalitis pan-
el, S. agalactiae (+) (BioFire)
S. mitis‖‖ No CSF bacterial culture (−); FilmArray 
Meningitis/Encephalitis panel (−) 
(SJCRH)
CSF bacterial 16S rRNA PCR assay,  
S. mitis group (+) (UW)
*  Plus signs indicate positive tests, and minus signs indicate negative tests. CDC denotes Centers for Disease Control and Prevention, EBV 
Epstein–Barr virus, EV enterovirus, HEV hepatitis E virus, HHV-6 human herpesvirus type 6, HSV-1 herpes simplex virus type 1, HSV-2 
herpes simplex virus type 2, ITS internal transcribed spacer, PCR polymerase chain reaction, PTLD post-transplantation lymphoprolifera-
tive disorder, qPCR quantitative PCR, rRNA ribosomal RNA, RT-PCR reverse-transcriptase PCR, SJCRH St. Jude Children’s Research Hospital, 
SLEV St. Louis encephalitis virus, UW University of Washington, and VZV varicella–zoster virus.
†  These are strains of enterovirus B.
‡  The patient, who was immunocompromised because of renal transplantation, made a full neurologic recovery after antiviral treatment with 
ganciclovir directed against EBV.
§  Both patients with HHV-6–associated encephalitis had undergone bone marrow transplantation for acute myelogenous leukemia and were 
treated with antiviral agents (ganciclovir, foscarnet, or both); HHV-6 limbic encephalitis occurring in this patient population is well described.13
¶  This child was immunocompromised because of bone marrow transplantation and had a history of disseminated candidiasis and persis-
tently elevated 1,3-β-D-glucan levels in CSF but negative CSF fungal culture. The patient was treated empirically with multiple courses of 
antibacterial agents (meropenem, vancomycin, cefepime, and ceftriaxone) and antifungal agents (caspofungin, fluconazole, and liposomal 
amphotericin B) before CSF samples were obtained for metagenomic NGS testing.
‖  This HIV-1–infected patient had the acquired immunodeficiency syndrome and a CD4 cell count of 40 and had received a diagnosis of an 
aggressive EBV-associated B-cell lymphoma on the basis of a liver biopsy. EBV-associated B-cell lymphoma of the CNS was not consid-
ered in the differential diagnosis until EBV was detected in the CSF by both metagenomic NGS and conventional confirmatory testing.
**  The patient was treated empirically with 8 days of piperacillin–tazobactam plus vancomycin followed by 32 days of meropenem plus van-
comycin in addition to gentamicin, linezolid, and fluconazole before CSF samples were obtained for metagenomic NGS testing.
††  The patient was treated empirically with 4 days of meropenem before CSF samples were obtained for metagenomic NGS testing.
‡‡  The patient was treated empirically for 6 hours with ceftriaxone, vancomycin, and metronidazole before CSF samples were obtained for 
metagenomic NGS testing. A total of 124 DNA metagenomic NGS sequences (out of 10.3 million) aligned to neisseria species, with Neisseria 
meningitidis being the closest match identified by SURPI+ (Sequence-based Ultra-Rapid Pathogen Identification). We subsequently generated 
an additional 355,366 metagenomic NGS sequences aligning to neisseria species by sequencing the CSF sample to a depth of approximately 
1.65 billion raw reads. Phylogenetic analysis of the gene encoding 50S ribosomal protein L6 (rplF), commonly used for neisseria identifica-
tion,14 positioned this species in the “Neisseria sicca/mucosa” subgroup (Fig. S2 in the Supplementary Appendix). However, because we can-
not be sure that this is the exact species, the confirmatory test result is reported as “neisseria, probably not N. meningitidis.”
§§  The patient was treated empirically with 8 days of piperacillin–tazobactam plus vancomycin before CSF samples were obtained for 
metagenomic NGS testing.
¶¶  The patient was treated empirically with 2 days of ceftriaxone or ceftazidime plus vancomycin before CSF samples were obtained for 
metagenomic NGS testing.
‖‖  The patient was treated empirically with meropenem, vancomycin, and amikacin immediately before CSF samples were obtained for 
metagenomic NGS testing.
Table 2. (Continued.)
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B Viral Genotyping (Coxsackievirus B5)
C Longitudinal Tracking of Viral Infection (MW Polyomavirus) E Analysis of Antibiotic-Resistance Genes
(Enterobacter aerogenes)
D Accurate Species Identification (Streptococcus mitis)
F Detection of Pathogen Reads below Reporting Threshold
 (Mycobacterium bovis)
No. of  MW
Polyomavirus
Reads
Time of Lumbar
Puncture
1st hospitalization
(acute meningo-
encephalitis)
1st hospitalization
(after recovery)
2nd hospitalization
(VZV uveitis)
244
16
0 and 12
S. pneumoniae
S. mitis
S. pyogenes
*
macA (1 read) (efflux pump):
macrolide resistance
acrA/B-tolC (16 reads) (efflux
pump): aminoglycoside,
beta-lactam, macrolide 
    resistance
mdtG (3 reads) (efflux pump):
fosfomycin resistance
mdtL (4 reads) (efflux pump):
chloramphenicol resistance
mexB (3 reads) (efflux pump):
aminoglycoside, beta-lactam,
fluoroquinolone, tetracycline
resistance
smeB (2 reads) (efflux pump):
fluoroquinolone resistance
 CMY-2 (4 reads) (AmpC 
β-lactamase): carbapenem 
resistance
emrD (2 reads) (efflux pump):
aminoglycoside resistance,
fluoroquinolone resistance
ksgA (2 reads) (16S rRNA
methyltransferase): kasuga-
mycin resistance
Detected Antibiotic-Resistance Genes
(Astrovirus MLB2)
*
*
*
*
Analytic, RNA prep
Cell reads
Sample reads
Species reads
Total reads
Blast NCBI nt
25,015
26,263
31,640
36,474
100.0%
95.2%
79.1%
68.6%
Analytic, RNA prep
Cell reads
Sample reads
Species reads
Total reads
Blast NCBI nt
110,415
114,395
225,845
272,484
100.0%
96.5%
48.9%
40.5%
Analytic, DNA prep
Cell reads
Sample reads
Species reads
Total reads
Blast NCBI nt
181
306
181
10,300
100.0%
59.2%
100.0%
1.8%
Analytic, DNA prep
Normalized
Cell reads
Sample reads
Species reads
Total reads
NTC reads
Blast NCBI nt
Blast NCBI wgs E. aerogenes
495.96
5,112
5,277
5,131
107,854
0
100.0%
96.9%
99.6%
4.7%
HIV-1
Enterovirus B
*
Analytic, DNA prep
Normalized
Cell reads
Sample reads
Species reads
Total reads
NTC reads
Blast NCBI nt
Blast NCBI wgs M. bovis
3.7793
56
820
87
949,353
17
100.0%
6.8%
64.4%
0.0%
Propionibacteriaceae
Enterobacteriaceae
Enterobacteriaceae
Mycobacteriaceae
*
Pseudomonadaceae
Comamonadaceae
Comamonadaceae
Alcaligenaceae
Comamonadaceae
Pseudomonadaceae
Pseudomonadaceae
Staphylococcaceae
Pseudomonadaceae
Moraxellaceae
Propionibacterium
*
Escherichia
Mycobacterium
*
Pseudomonas
Acidovorax
Acidovorax
Achromobacter
Acidovorax
Pseudomonas
Pseudomonas
Staphylococcus
Pseudomonas
Acinetobacter
P. acnes
*
E. coli
*
*
*
*
A. ebreus
A. xylosoxidans
Acidovorax species, JS42
P. putida
P. stutzeri
S. epidermidis
P. aeruginosa
A. baumannii
E. aerogenes
*
*
*
Torque teno virus
Simian–human immunodeficiency virus
Betapapillomavirus 2
Murine leukemia virus
Murine leukemia virus
Enterovirus A
Human echovirus AMS573
GB virus C
GB virus C
Human echovirus AMS721
HIV
Human herpesvirus 5
Human herpesvirus 5
Human herpesvirus 5
Human herpesvirus 6B
*
MX polyomavirus
Torque teno virus
Polyomavirus
MW polyomavirus
Betapapillomavirus 2
Ungulate tetraparvovirus 1
Human herpesvirus 1
*
Torque teno virus 14
Human herpesvirus 7
HIV-1
K. pneumoniae
*
Analytic, RNA prep
Cell reads
Sample reads
Species reads
Total reads
Blast NCBI nt
5
5
5
3538
100.0%
100.0%
100.0%
0.1%
Astrovirus MLB2
*
GB virus C
Murine leukemia virus
Cotesia congregata bracovirus
*
*
Betapapillomavirus 1
HIV-1
S. suis
S. pyogenes
Serratia marcescens
S. macedonicus
S. mitis
S. pseudopneumoniae
S. suis
S. oligofermentans
S. mutans
S. anginosus
Streptococcus species, VT 162
S. pneumoniae
Klebsiella pneumoniae
Bifidobacterium dentium
*
*
*
*
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ism in CSF samples with a high host background 
(i.e., samples in which the normalized read 
counts corresponding to the internal spiked DNA 
or RNA control did not meet preestablished 
thresholds), our findings suggest that a negative 
test in this context should be interpreted with 
caution owing to the higher risk of false nega-
tive results. However, metagenomic NGS that is 
performed in combination with conventional 
testing may potentially be useful for ruling out 
an active infection in patients with suspected 
autoimmune encephalitis, who typically present 
with only mild-to-moderate lymphocytic pleocy-
tosis (<100 cells per cubic millimeter)28 and thus 
low host background in CSF. Treating clinicians 
are often reluctant to initiate immunosuppres-
sive therapies for autoimmune disease without a 
reasonably high degree of confidence that an 
occult infection has not been missed.
Our data show that clinical metagenomic NGS 
of CSF represents a potential step forward in the 
diagnosis of meningoencephalitis. This diagnos-
tic approach may guide earlier and more targeted 
treatments for neuroinvasive infections, identify 
emerging infections and disease phenotypes, and 
accelerate the workup and treatment for nonin-
fectious causes. The preferred timing and patient 
population for clinical metagenomic NGS testing 
remain to be defined through further research.
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Figure 3 (facing page). Supplementary Metagenomic 
NGS Analyses.
Supplementary analyses of the metagenomic NGS data were 
performed and results discussed during weekly teleconfer-
ences with the clinical microbial sequencing board. The as-
terisk denotes the column on the interactive SURPI+ heat 
map corresponding to the patient’s CSF sample, and pop-up 
windows highlight the cell corresponding to the given species 
hit (see Supplementary Appendix for additional details). For 
Panels A and B, the green tracing corresponds to the cover-
age at a given nucleotide position (y axis, left), and the pur-
ple tracing corresponds to the pairwise identity (y axis, right) 
after automated mapping by SURPI+ of metagenomic NGS 
reads to the most closely matched viral reference genome 
in the National Center for Biotechnology Information (NCBI) 
nucleotide (nt) database. Panel A shows prediction of resis-
tance to antiviral drugs. Mapping HIV-1 reads from a patient 
CSF sample to the most closely matched genome in the 
reference database shows that the complete viral genome 
can be assembled (middle), thus enabling prediction of anti-
viral drug resistance (right). Predicted z scores were obtained 
with the use of Web-based geno2pheno software.19 The z 
scores corresponding to a subset of commonly prescribed 
antiretroviral drugs (black) are shown relative to reference 
z-score ranges for susceptible (green), intermediate (yellow), 
or resistant (orange) phenotypes. 3TC denotes lamivudine, 
ABC abacavir, ATZ/r ritonavir-boosted atazanavir, DRV/r 
ritonavir-boosted darunavir, EFV efavirenz, LPV/r ritonavir-
boosted lopinavir, NNRTI nonnucleoside reverse-transcrip-
tase inhibitor, NRTI nucleoside reverse-transcriptase inhibi-
tor, NVP nevirapine, PI protease inhibitor, TDF tenofovir, and 
ZDV zidovudine. Panel B shows viral genotyping. The viral 
genome in an enterovirus B–positive case was assembled 
from metagenomic NGS reads, and the specific viral strain 
was identified as coxsackievirus B5 by SURPI+ (right). Panel 
C shows longitudinal tracking of viral infection. MW polyoma-
virus, originally identified in stool from children with diar-
rhea,18 was detected in an immunocompromised child pre-
senting with acute meningoencephalitis. The finding was 
thought to be of unclear clinical significance, although no 
other infectious cause was identified. Zero and 12 reads to 
MW polyomavirus were detected in two CSF samples ob-
tained 3 months later, during a second hospitalization for 
documented varicella–zoster virus (VZV) uveitis. Panel D 
shows accurate species identification. Assembly of the full-
length 16S rRNA gene from metagenomic NGS reads en-
abled phylogenetic analysis and assignment of the species 
as Streptococcus mitis. A phylogenetic tree was obtained by 
aligning 25 representative S. mitis and 25 representative 
Streptococcus pneumoniae strains (with Streptococcus pyo-
genes as an outgroup) with the patient’s 16S rRNA sequence 
with the use of MAFFT20 at default settings, followed by tree 
construction with the use of PhyML.21 Panel E shows analy-
sis of antibiotic-resistance genes. Such genes were identified 
by alignment of Enterobacter aerogenes (now renamed Kleb-
siella aerogenes) metagenomic NGS reads to the comprehen-
sive antibiotic-resistance database.22 Panel F shows the de-
tection of pathogen reads below the reporting threshold, 
with heat maps corresponding to two pathogens (Mycobac-
terium bovis and astrovirus MLB2) that were not reported 
as positive by metagenomic NGS because the number and 
distribution of reads did not meet preestablished thresholds.9 
In Panels E and F, AmpC denotes class C β-lactamase, and 
wgs the NCBI whole-genome shotgun database.
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